BioCentury | Mar 1, 2019
Financial News

Blackstone, Novartis spin out cardiovascular newco Anthos

...Novartis will retain an undisclosed minority stake in the company. MAA868 is an inhibitor of Factor XI...
BioCentury | Feb 27, 2019
Company News

Blackstone, Novartis spin out cardiovascular newco Anthos

...Novartis will retain an undisclosed minority stake in the company. MAA868 is an inhibitor of Factor XI...
BioCentury | Apr 14, 2017
Clinical News

Personal Genome Service Genetic Health Risk (GHR) test regulatory update

...AD), celiac disease, alpha-1 antitrypsin ( AAT ; A1AT ; SERPINA1) deficiency, early-onset primary dystonia, Factor XI...
BioCentury | Mar 8, 2017
Translation in Brief

Up to eleven

...Translational Medicine study from Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and Johannes Gutenberg University Mainz has shown Factor XI-targeting...
...targeting Factor XI or Factor XIa, including Ionis and Bayer AG (Xetra:BAYN). The partners have the anti-Factor XI...
...scientists showed a similar ASO targeting rodent Factor XI protected mice and rats from hypertension, suggesting Factor XI...
BioCentury | Feb 22, 2017
Distillery Therapeutics

Cardiovascular

...INDICATION: Hypertension Mouse and rat studies suggest inhibiting Factor XI could help treat arterial hypertension and consequent...
...and consequent tissue damage. In a mouse model of arterial hypertension, an antisense oligonucleotide targeting Factor XI...
...pressure or organ damage. Ionis Pharmaceuticals Inc. and Bayer AG have BAY 2306001 , a Factor XI...
BioCentury | Feb 17, 2017
Company News

Ionis, Bayer deal

...payment from Bayer tied the development of anticoagulants IONIS-FXIRx (BAY 2306001) and IONIS-FXI-LRx , both Factor XI...
...be eligible for milestones plus tiered royalties. In November 2016, Ionis said IONIS-FXIRx significantly reduced Factor XI...
...Pharmaceuticals Inc. (NASDAQ:IONS), Carlsbad, Calif. Bayer AG (Xetra:BAYN), Leverkusen, Germany Business: Cardiovascular Chris Lieu IONIS-FXIRx Bayer AG Ionis Pharmaceuticals Inc. Factor XI IONIS-FXI-LRx...
BioCentury | Feb 14, 2017
Company News

Ionis gets $75M milestone in Bayer anticoagulant deal

...$75 million milestone payment from Bayer AG (Xetra:BAYN) tied to milestones in the development of Factor XI...
...be eligible for milestones plus tiered royalties. In November, Ionis said that IONIS-FXIRx significantly reduced Factor XI...
...in a Phase II trial. Ionis gained $0.90 to $46.99 on Tuesday. Chris Lieu IONIS-FXIRx Bayer AG Ionis Pharmaceuticals Inc. Factor XI...
BioCentury | Dec 9, 2016
Clinical News

SPK-9001: Additional Ph I/II data

...in circulating Factor IX activity Status: Additional Phase I/II data Milestone: NA Alex Himes SPK-9001 Pfizer Inc. Spark Therapeutics Inc. Factor XI American...
BioCentury | Dec 1, 2016
Clinical News

IONIS-FXIRx: Ph II data

...dosed twice weekly for 2 weeks and then once weekly for 10 weeks reduced mean Factor XI...
...IONIS-FXIRx , BAY 2306001 , ISIS 416858 (formerly ISIS-FXIRx) Business: Cardiovascular Molecular target: Factor XI Description: Factor XI...
...Endpoint: Safety; pharmacodynamics and pharmacodynamics Status: Phase II data Milestone: NA Alex Himes BAY 2306001 IONIS-FXIRx Bayer AG Ionis Pharmaceuticals Inc. Factor XI...
BioCentury | Sep 29, 2016
Product R&D

Safety Factor

...and Factor XI - proteases in the coagulation cascade that contribute to clot formation. But whereas Factor XI...
...However, Factor XI garnered the attention of companies and academics after results from human studies linked Factor XI...
...to targeting Factor XI instead of Factor XIa. "I think an antibody that targets the zymogen Factor XI...
Items per page:
1 - 10 of 32